Veracyte’s patent involves methods, systems, and kits for diagnosing, prognosing, and determining cancer progression, specifically prostate cancer. The invention includes biomarkers, classifiers, and probe sets for subtyping prostate cancer in a subject. Treatment methods based on molecular subtyping are also provided, such as administering androgen deprivation therapy to those with the luminal B subtype. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Subtyping prostate cancer for treatment based on gene expression
A recently granted patent (Publication Number: US11873532B2) outlines a method for diagnosing and treating prostate cancer based on genomic subtyping. The method involves providing a biological sample from a subject with prostate cancer, extracting nucleic acids, detecting the presence or expression levels of specific targets, and subtyping the cancer according to a genomic classifier to assign it to a luminal B subtype. Subsequently, the method involves administering androgen deprivation therapy to subjects with the luminal B subtype, offering a targeted treatment approach based on the genetic characteristics of the cancer.
Furthermore, the patent describes the selection of subjects with the luminal B subtype of prostate cancer based on the genomic classifier and the expression levels of specific targets in biological samples. The treatment for these subjects involves androgen deprivation therapy. The patent also specifies various types of biological samples that can be used for analysis, including biopsy, urine, blood (plasma, serum, or whole blood), or prostate tumor samples. Additionally, the patent details methods for determining the levels of expression, such as in situ hybridization, PCR-based methods, array-based methods, immunohistochemical methods, RNA assay methods, or immunoassay methods, using reagents like nucleic acid probes, primers, or antibodies, and measuring RNA transcript levels.
To know more about GlobalData’s detailed insights on Veracyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
